The purpose of this study was to evaluate the long-term outcome of interferon (IFN) alfa
treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia …

To evaluate the long‐term impact of the reduction of Philadelphia chromosome (Ph)‐positive
metaphases by treatment of chronic myelogenous leukaemia (CML) with interferon (IFN) …

In a prospective multicenter phase-II trial 80 patients with Philadelphia (Ph)-positive chronic
myelogenous leukemia (CML) were treated with recombinant interferon (IFN) α-2c …

131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia
(CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN …

Several prospective randomized studies have shown that the treatment of chronic myeloid
leukemia with interferon-(IFN-) prolongs the survival by comparison with conventional …

In a series of studies spanning 14 years, investigators from MD Anderson Cancer Center
(Houston, TX) documented the activity of interferon-alfa (IFN-alpha) in chronic myelogenous …

Several studies have shown that interferon IFN-alpha can produce durable complete
hematological remission and in some patients complete cytogenetic remission. This latter …

Interferon-alfa (IFNα) became the first-line agent for the treatment of chronic myeloid
leukemia (CML) because it prolongs survival significantly compared to conventional …

Background: Several randomized clinical trials in chronic myeloid leukemia (CML) have
reported better patient survival with interferon alfa (IFN α) than with standard …

The objective of the study was to investigate the toxicity and efficacy of cyclic combination
therapy offered to patients with Ph-positive CML having a sub-optimal response to IFN-α …